rat-specific goat polyclonal pan- vegf antibody  (R&D Systems)

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Limbal vessel dilation, inflammatory cell infiltration and Vegfa expression following IgG, anti- Vegf and dexamethasone treatment of suture-induced injury in the rat cornea. ( A ) Slit lamp photographs depicting limbal vessel dilation and looping angiogenesis 48 h after suture placement in IgG and anti- Vegf groups, not detected in the dexamethasone group; expanded view of the white boxed area in ( B ). ( C ) IVCM images of limbal vessel dilation, and the corresponding measurements of limbal vessel diameter in ( G ); ( D ) Microscopic images of aqueous humor cellular content, and the corresponding quantification in ( H ). ( E ) Immunofluorescence of Vegfa (green) and DAPI counterstaining of nuclei (blue) in corneal tissue sections. ( F ) CD31 staining (green) of naïve and sutured cornea at 48 hours: the latter shows no sign of corneal neovascularization. n = 4 corneas per group for ( G) and ( H) , *P < 0.05; **P < 0.01; ***P < 0.001; n.s. = P > 0.05 and error bars represent SD.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Expressing, Immunofluorescence, Staining

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Differentially expressed genes (DEGs) in IgG, dexamethasone and anti- Vegf treated groups, and selected enriched biological processes. ( A–C) Volcano plots of the DEGs in IgG, dexamethasone and anti- Vegf groups respectively. (D) Selected biological processes of interest, indicating the number of DEGs involved in the processes for each treatment.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques:

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: The top 10 differentially up- and downregulated genes involved in selected biological processes (a), and in selected pathways (b).

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques:

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Pathway enrichment analysis indicates that dexamethasone suppresses most DEGs in all selected inflammatory and angiogenesis pathways, relative to IgG and anti- Vegf treatment.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques:

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: ( A–G ): Immunofluorescent staining of naïve, and sutured corneas from treatment groups (48 h post-suture). Factors most differentially regulated between dexamethasone and anti- Vegf groups from microarray analysis are shown. Expression signals are indicated in green, and DAPI counterstained nuclei in blue. Scale bar = 50 µm. ( H–J ): qPCR analysis of C3 , C1s and Vegfa gene expression. The error bars represent SEM.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Staining, Microarray, Expressing, Gene Expression

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Summary of genes involved in the complement cascade from gene microarray analysis, and the FC Diff and the corresponding P values.

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Microarray, Binding Assay, Virus

Journal: Scientific Reports

Article Title: Genome-wide expression differences in anti- Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea

doi: 10.1038/s41598-017-07129-4

Figure Lengend Snippet: Summary of complement genes differentially regulated by dexamethasone treatment relative to anti- Vegf , and their roles in the complement cascade based on gene expression microarray analysis. Differentially regulated genes (upregulated genes labelled in red, downregulated genes in green) are shown along with their fold change difference (dexamethasone minus anti- Vegf ) and corresponding p-value (between dexamethasone and anti- Vegf fold change) given in parentheses. All differentially regulated genes mapped to the classical pathway, while Cfi , a natural inhibitor of C3 and C5 convertase production, was strongly downregulated. This, combined with strong upregulation of C3 , promoted pathways leading to inflammatory cell activation and invasion into the cornea following dexamethasone treatment. Further downstream complement components ( C6 – C9 ) leading to cell lysis were not differentially regulated by dexamethasone. The figure is an adapted version of the conceptual diagram presented by del Zoppo .

Article Snippet: The time of suture placement was designated as 0 h. Sutured animals were randomly assigned to one of three topical treatment groups: Rat-specific goat polyclonal pan- Vegf antibody (20 μg/ml, Cat. No AF 564, R&D Systems, Minneapolis MN, USA).

Techniques: Gene Expression, Microarray, Activation Assay, Lysis

Journal: American Journal of Physiology - Lung Cellular and Molecular Physiology

Article Title: VEGF in the lung: a role for novel isoforms

doi: 10.1152/ajplung.00353.2009

Figure Lengend Snippet: Representative expression of VEGF xxx b expression in normal and acute respiratory distress syndrome (ARDS) lung detected by immunocytochemistry. A and C are IgG isotopic controls, normal and ARDS lung, respectively. In B , extensive VEGF xxx b is present in normal lung, particularly in alveolar type II (ATII) cells (arrow). In D , there is much less VEGF xxx b staining in the lung tissue per se, but more is present in infiltrating inflammatory cells (arrow).

Article Snippet: After three washes with PBST, 100 μl/well of a biotinylated goat polyclonal antibody anti-human Pan VEGF (AF293B, R&D Systems), at 50 ng/ml in PBS, was added.

Techniques: Expressing, Immunocytochemistry, Staining

Journal: American Journal of Physiology - Lung Cellular and Molecular Physiology

Article Title: VEGF in the lung: a role for novel isoforms

doi: 10.1152/ajplung.00353.2009

Figure Lengend Snippet: ELISA performed on bronchoalveolar lavage fluid from healthy control subjects, patients “at risk,” and with ARDS ( n = 8) showing a significant reduction in VEGF 165 b in at-risk subjects compared with healthy controls (* P < 0.05).

Article Snippet: After three washes with PBST, 100 μl/well of a biotinylated goat polyclonal antibody anti-human Pan VEGF (AF293B, R&D Systems), at 50 ng/ml in PBS, was added.

Techniques: Enzyme-linked Immunosorbent Assay, Control